Inhibikase Therapeutics

NAQ:IKT · US45719W2052

BiotechnologySmall

360° View

Value28

Price/Sales7

Price/Earnings43

Price/Book54

Dividend Yield—

Growth21

Revenue Growth1

Profit Growth77

Capital Growth1

TSR 52w22

Safety41

Leverage82

Liquidity20

Refinancing40

Combined13

Sentiment39

Analyst Opinions81

Pro Holdings49

Opinion Changes50

Market Pulse8

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Founded2010

Employees26

Websiteinhibikase.com

ISINUS45719W2052

Last UpdateApr 2, 2026

Index & Theme

HematologyCardiovascularGastroenterologyNeurologyInfectious DiseasesOncologyHealth CareHealth DiagnosticsTherapeutics

Description

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (‘PAH’), in which aberrant signaling through t…

Analysis

Inhibikase Therapeutics's 360° View rank of 10 places it among the weakest overall — better than 10% of its true peers.

It's lagging on growth (21) and on the expensive side (28). On safety it is carrying more balance-sheet risk (41), and the market shows muted sentiment (39). Taken together, its Combined rank of 13 reads as among the weakest overall.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Inhibikase Therapeutics with its peers

Tenax Therapeutics

NAQ:TENX

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Arbutus Biopharma

NSQ:ABUS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Gossamer Bio

NSQ:GOSS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

MannKind

NMQ:MNKD

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

United Therapeutics

NSQ:UTHR

CountryUSA

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Pyxis Oncology

NSQ:PYXS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →